A fused heterocyclic compound represented by formula I, pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, Wherein, A 1 is N; A 2 is N; R 2 is -(CR 8 R 9 ) m NR 5 R 6 , -(CR 8 R 9 ) m NR 7 C(=Y)R 5 , -(CR 8 R 9 ) m NR 7 S(O) 2 R 5 , -(CR 8 R 9 ) m OR 5 , -(CR 8 R 9 ) m S(O) 2 R 5 , -(CR 8 R 9 ) m S(O) 2 NR 5 R 6 , -C(OR 5 )R 6 R 8 , -C(=Y)R 5 , -C(=Y)OR 5 , -C(=Y)NR 5 R 6 , -C(=Y)NR 7 OR 5 , -C(=O)NR 7 S(O) 2 R 5 , -C(=O)NR 7 (CR 8 R 9 ) m NR 5 R 6 , -NR 7 C(=Y)R 6 , -NR 7 C(=Y)OR 6 , -NR 7 C(=Y)NR 5 R 6 , -NR 7 S(O) 2 R 5 , -NR 7 S(O) 2 NR 5 R 6 , -SR 5 , -S(O) 2 R 5 , -S(O) 2 NR 5 R 6 , -SC(=Y)R 5 , -SC(=Y)OR 5 , -O(CR 8 R 9 ) m NR 5 R 6 , a C 1-12 alkyl, a C 2-8 alkenyl, a C 2-8 alkynyl, a C 3-12 carbocyclic group, a C 2-20 heterocyclic group, a C 6-20 aryl or a C 1-20 heteroaryl; or R 2 has a structure selected from the group consisting of (R 3 ) k represents that the hydrogens attached to the morpholine ring are substituted by 0-k occurrences of R 3 , at each occurrence the R 3 is the same or different from each other, and is independently a hydrogen, a deuterium, a halogen, a C 1-6 alkyl, or any two of the R 3 are linked by a single bond, a C 1-6 alkylene or a C 1-6 alkylene substituted by one or two heteroatoms to form a ring structure, the heteroatom is O, N, or S; A is N or CR 4a ; D is N; E is N or CR 4e ; G is CR 4g ; R 4g is -NR 7 S(O) 2 R 5 ; J is N or CR 4j ; R 4a , R 4e and R 4j are each independently a hydrogen, a halogen, -CN, an alkyl, an alkoxy, an alkenyl, an alkynyl, a cycloalkyl, a heterocycloalkyl, -NR 5 R 6 , -OR 5 , -SR 5 , -C(O)R 5 , -NR 5 C(O)R 6 , -N(C(O)R 6 ) 2 , -NR 5 C(O)NR 5' R 6 , -NR 7 S(O) 2 R 5 , -C(=O)OR 5 or -C(=O)NR 5 R 6 ; ring Q is benzene; at each occurrence the R 1 is the same or different from each other, and is each independently a halogen, -CN, an alkyl, an alkoxy, an alkenyl, an alkynyl, a cycloalkyl, a heterocycloalkyl, -NR 5 R 6 , -OR 5 , -SR 5 , -C(O)R 5 , -NR 5 C(O)R 6 , -N(C(O)R 6 ) 2 , -NR 5 C(O)NR 5' R 6 , -NR 7 S(O) 2 R 5 , -C(=O)OR 5 or -C(=O)NR 5 R 6 ; R 5 , R 5' , R 6 , R 7 and R 7' are each independently a hydrogen, a C 1-12 alkyl, -(CH 2 ) 2-3 NH 2 , a C 2-8 alkenyl, a C 2-8 alkynyl, a C 3-12 carbocyclic group, a C 2-20 heterocyclic group, a C 6-20 aryl or a C 1-20 heteroaryl, or R 5 , R 6 together with the nitrogen or carbon atoms to which they are directly attached form a heterocyclic ring or a cycloalkyl; or R 7 , R 7' together with the nitrogen atom to which R 7 is directly attached form a heterocyclic ring; the heterocyclic ring or the cycloalkyl is optionally substituted by the substituent selected from the group consisting of oxo, -(CH 2 ) m OR 7 , -NR 7 R 7' , -CF 3 , a halogen, -SO 2 R 7 , -C(=O)R 7 , -NR 7 C(=Y)R 7' , -NR 7 S(O) 2 R 7' , -C(=Y)NR 7 R 7' , a C 1-12 alkyl, a C 2-8 alkenyl, a C 2-8 alkynyl, a C 3-12 carbocyclic group, a C 2-20 heterocyclic group, a C 6-20 aryl and a C 1-20 heteroaryl; (CR 8 R 9 ) m represents that 0 to m (CR 8 R 9 ) are linked with each other, R 8 and R 9 are the substituents attached to the formed carbon chain, wherein each R 8 and R 9 is the same or different from each other, and is each independently a hydrogen, a deuterium, a halogen, -CN, a hydroxyl, an alkoxy, a C 1-12 alkyl, a C 2-12 alkenyl, a C 2-12 alkynyl, a C 3-12 cycloalkyl, a C 6-12 aryl, a 3- to 12-membered heterocycloalkyl or a 5- to 12-membered heteroaryl; or R 8 , R 9 together with the atoms to which they are attached form a saturated or partially unsaturated C 3-12 carbon ring or C 2-20 heterocyclic ring; wherein the alkyl, carbocyclic ring and heterocyclic ring can be optionally substituted by the substituent selected from the group consisting of a halogen, a hydroxyl, -CN, -CF 3 , -NO 2 , oxo, -(CR 8 R 9 ) m OR 5 and a C 2-20 heterocyclic group; Y is O, S or NR 7 ; m, k or k1 is independently 0, 1, 2, 3, 4, 5 or 6. <EOS>